Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Open original sourceLoading market dashboard
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Open original source